The discovery of miRNAs in the mid-90s has changed the dogma of gene expression
regulation. Currently, miRNAs are the main theme of thousands of publications each year …

miRNAs, short ribonucleic acid gene regulators, are increasingly popular drug targets.
Traditionally 'undruggable'proteins can be targeted via their miRNA gene regulators …

MicroRNAs are a class of small non-coding RNAs (22-23 nucleotides), which regulate gene
expression at the posttranscriptional level and play key roles in tumorigenesis and other …

RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs,
were approved by the Food and Drug Administration in 2018 and 2019, respectively …

In just over two decades since the discovery of the first microRNA (miRNA), the field of
miRNA biology has expanded considerably. Insights into the roles of miRNAs in …

Background miRNAs, a class of small endogenous RNAs, are one of the essential
biopharmaceuticals which are in commercial spans as next-generation medicine in recent …

miRNAs are small noncoding RNAs that control gene expression at the posttranscriptional
level. It has been recognised that miRNA dysregulation reflects the state and function of cells …

The knowledge that miRNA expression is frequently dysregulated in cancer has uncovered
an entirely new repertoire of molecular factors upstream of gene expression, with exciting …

In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are
some of the most important biopharmaceuticals that are in commercial space as future …

The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …